220 related articles for article (PubMed ID: 23490199)
1. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy.
Légaré N; Grégoire CA; De Benedictis L; Dumais A
Med Hypotheses; 2013 Jun; 80(6):689-91. PubMed ID: 23490199
[TBL] [Abstract][Full Text] [Related]
2. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients.
Lu ML; Lane HY; Chen KP; Jann MW; Su MH; Chang WH
J Clin Psychiatry; 2000 Aug; 61(8):594-9. PubMed ID: 10982203
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
Lu ML; Lane HY; Lin SK; Chen KP; Chang WH
J Clin Psychiatry; 2004 Jun; 65(6):766-71. PubMed ID: 15291653
[TBL] [Abstract][Full Text] [Related]
5. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
[TBL] [Abstract][Full Text] [Related]
6. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
7. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
Lu ML; Chen TT; Kuo PH; Hsu CC; Chen CH
Schizophr Res; 2018 Mar; 193():126-133. PubMed ID: 28688742
[TBL] [Abstract][Full Text] [Related]
8. Navigating the co-prescription of clozapine and fluvoxamine.
Shymko G; Clark V; Shymko L; Waters F
Schizophr Res; 2018 Dec; 202():391-393. PubMed ID: 30269927
[No Abstract] [Full Text] [Related]
9. Dosing strategies of clozapine-fluvoxamine cotreatment.
Lu ML; Lane HY; Jann MW; Chang WH
J Clin Psychopharmacol; 2002 Dec; 22(6):626-8. PubMed ID: 12454566
[No Abstract] [Full Text] [Related]
10. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
Costa-Dookhan KA; Agarwal SM; Chintoh A; Tran VN; Stogios N; Ebdrup BH; Sockalingam S; Rajji TK; Remington GJ; Siskind D; Hahn MK
Expert Opin Drug Saf; 2020 Jan; 19(1):43-57. PubMed ID: 31770500
[No Abstract] [Full Text] [Related]
11. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.
Ozdemir V; Kalow W; Okey AB; Lam MS; Albers LJ; Reist C; Fourie J; Posner P; Collins EJ; Roy R
J Clin Psychopharmacol; 2001 Dec; 21(6):603-7. PubMed ID: 11763009
[TBL] [Abstract][Full Text] [Related]
12. Making sense of norclozapine levels: 3 clinical axioms.
Meyer JM
Schizophr Res; 2024 Jun; 268():289-292. PubMed ID: 37945386
[TBL] [Abstract][Full Text] [Related]
13. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models.
Yuen JWY; Wu C; Wang CK; Kim DD; Procyshyn RM; Honer WG; Barr AM
Neuropharmacology; 2020 Sep; 175():107717. PubMed ID: 31348941
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.
Tan MSA; Honarparvar F; Falconer JR; Parekh HS; Pandey P; Siskind DJ
Psychopharmacology (Berl); 2021 Mar; 238(3):615-637. PubMed ID: 33410989
[TBL] [Abstract][Full Text] [Related]
16. High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis.
Leising J; Barr AM; Procyshyn RM; Ainsworth NJ; White RF; Honer W; Vila-Rodriguez F
J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):186-190. PubMed ID: 33587389
[TBL] [Abstract][Full Text] [Related]
17. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.
Hasegawa M; Gutierrez-Esteinou R; Way L; Meltzer HY
J Clin Psychopharmacol; 1993 Dec; 13(6):383-90. PubMed ID: 8120151
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients.
Hermida J; Paz E; Tutor JC
Ther Drug Monit; 2008 Feb; 30(1):41-5. PubMed ID: 18223461
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience.
Lammers CH; Deuschle M; Weigmann H; Härtter S; Hiemke C; Heese C; Heuser I
Pharmacopsychiatry; 1999 Mar; 32(2):76-7. PubMed ID: 10333167
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.
Li LJ; Shang DW; Li WB; Guo W; Wang XP; Ren YP; Li AN; Fu PX; Ji SM; Lu W; Wang CY
Acta Pharmacol Sin; 2012 Nov; 33(11):1409-16. PubMed ID: 22820910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
